[
  {
    "ts": null,
    "headline": "First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity",
    "summary": "PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyondGlobal interim Phase 2 data showed a 76.3% confirmed objective response rate (cORR), 100% disease control rate (DCR), a median progression free survival (mPFS) of 6.8 months and a manageable safety profi",
    "url": "https://finnhub.io/api/news?id=3823ec415bc0a8a510f9c2ec124b912208ac67a880c06ec93e5d626cb8250e84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757347200,
      "headline": "First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity",
      "id": 136689615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyondGlobal interim Phase 2 data showed a 76.3% confirmed objective response rate (cORR), 100% disease control rate (DCR), a median progression free survival (mPFS) of 6.8 months and a manageable safety profi",
      "url": "https://finnhub.io/api/news?id=3823ec415bc0a8a510f9c2ec124b912208ac67a880c06ec93e5d626cb8250e84"
    }
  },
  {
    "ts": null,
    "headline": "Investing in Oncology: 3 Cancer Stocks With Promising Pipelines",
    "summary": "Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.",
    "url": "https://finnhub.io/api/news?id=02c685ac8dfbbeca17a408004c250987e0afabc680a0cc7b012a40defe6de411",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757342520,
      "headline": "Investing in Oncology: 3 Cancer Stocks With Promising Pipelines",
      "id": 136674206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.",
      "url": "https://finnhub.io/api/news?id=02c685ac8dfbbeca17a408004c250987e0afabc680a0cc7b012a40defe6de411"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
    "summary": "Get the latest on Bristol-Myers Squibb's growth strategy, new drug launches, R&D pipeline,",
    "url": "https://finnhub.io/api/news?id=0e6ab29a31fe824f561dccfc21a8d1a07f8c46a1ba92c66ed36617670c32e420",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757333715,
      "headline": "Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
      "id": 136670714,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Get the latest on Bristol-Myers Squibb's growth strategy, new drug launches, R&D pipeline,",
      "url": "https://finnhub.io/api/news?id=0e6ab29a31fe824f561dccfc21a8d1a07f8c46a1ba92c66ed36617670c32e420"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point",
    "summary": "Bristol-Myers Squibbâs strong oncology sales and upcoming approvals make its stockâs risk/reward profile increasingly attractive. Read more here on BMY stock here.",
    "url": "https://finnhub.io/api/news?id=e1c9b0b9fdecd0ec7458ae8850bbc3edb9bed3985e2a2c5b877217882f2dabc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757324865,
      "headline": "Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point",
      "id": 136668842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227488268/image_1227488268.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibbâs strong oncology sales and upcoming approvals make its stockâs risk/reward profile increasingly attractive. Read more here on BMY stock here.",
      "url": "https://finnhub.io/api/news?id=e1c9b0b9fdecd0ec7458ae8850bbc3edb9bed3985e2a2c5b877217882f2dabc0"
    }
  }
]